9 Jun 2011 10:00
9 June 2011
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Directorate change
Dr Steven Powell steps down from the Company
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that Dr Steven Powell has, by mutual agreement, resigned from the board of directors of the Company.
On 11 March 2011 the Company announced that Dr Powell had been granted a period of extended leave for a serious medical condition. Dr Powell is still receiving treatment for that condition and is unable to fulfill operational duties for the foreseeable future. He has therefore, by mutual agreement, resigned as a director with immediate effect.
Bill Robinson, Chairman, Plethora said:
"It is with sadness that Steven leaves the Company. As the founding CEO, he has been instrumental in driving the business forwards. During his tenure the Company listed on AIM and brought its lead product, PSD502, from concept to successful completion of phase III clinical studies. In 2009 he lead the development of The Urology Company, the UK headquartered sales and marketing business. We owe Steven a debt of gratitude for his unrelenting effort, energy and commitment. Our thoughts are with Steven and his family and we wish him a successful recovery."
-Ends-
Enquiries:
Plethora Solutions Ronald Openshaw | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Antony Legge (Nomad) Martin Lampshire (Broker) | Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
Hansard Communications Nicholas Nelson/Guy McDougall | Tel: +44(0) 20 7245 1100
|
Notes to Editors:
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).
Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.
The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com